FMT In High-Risk Acute GVHD After ALLO HCT

  • End date
    May 1, 2023
  • participants needed
  • sponsor
    Massachusetts General Hospital
Updated on 8 October 2021


The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant (FMT) treatment in high-risk acute graft-versus-host disease (GVHD).

This research study involves an experimental intervention called FMT.


In this research study, the investigators are evaluating the effectiveness of Fecal Microbiota Transplant (FMT) treatment in high-risk acute GVHD. The investigators are evaluating the effectiveness of FMT (also known as 'stool transplantation' or 'fecal transplant') in being able to transfer gut organisms from a healthy donor to the patient.

The investigators are also evaluating the ability of this treatment to improve or completely resolve the clinical symptoms (diarrhea, abdominal pain, rash, liver inflammation) that can occur with acute GVHD.This research study is a Pilot Study, which is the first time investigators are examining this intervention for treatment of acute GVHD.

The FDA (the U.S. Food and Drug Administration) has not approved FMT for this use. The FDA has classified human stool as a biological agent and determined that its use in FMT therapy should be regulated to ensure patient safety. To use FMT to treat recurrent Clostridium difficile infection, the most common indication for FMT, does not require an investigation new drug permit. To use FMT for research or to treat any condition other than recurrent Clostridium difficile infection requires an investigation new drug permit. An investigation new drug permit has been obtained for this study.

  • After HCT, the body's microbiome (the natural existence of various bacteria and organisms) in the intestinal tract may be affected, in that the number and types of good bacteria is reduced (also called a reduction in microbial flora diversity). Studies have shown that the number and types of good bacteria in the gut can impact whether or not graft-versus-host disease (GVHD) is developed. GVHD occurs when donated bone marrow cells attack the body with an immune response.
  • FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur the body. Since may have decreased microbial flora diversity after HCT, these microbial components are taken from a stool donor. They are extracted from fecal matter (stool) and put into a capsule to ingest.

Condition Stem Cell Transplant, Hematopoietic Stem Cell Transplantation, HSCT, Fecal Microbiota Transplant, Hematopoietic Cell Transplantation, Acute Graft-Versus-Host Disease (Gvhd) Grade, Stem Cell Transplantation, Hematopoietic Stem Cell Transplant, Allo-Hematopoietic Stem Cell Transplant, Allogeneic Hematopoietic Stem Cell Transplant
Treatment fecal microbiota transplant
Clinical Study IdentifierNCT04139577
SponsorMassachusetts General Hospital
Last Modified on8 October 2021


Yes No Not Sure

Inclusion Criteria

Men or women 18 years old
Patient has undergone allogeneic hematopoietic cell transplantation from any donor (related or unrelated with any degree of HLA matching) and any donor source (bone marrow, peripheral blood stem cells, or cord blood) for a hematologic malignancy or disorder. Recipients of myeloablative and reduced-intensity conditioning regimens are eligible
Evidence of myeloid engraftment (eg, absolute neutrophil count 0.5 109/L for 3 consecutive assessments if ablative therapy was previously used). Use of growth factor supplementation is allowed
Patient must have clinically suspected Grade II to IV aGVHD as per MAGIC criteria. Clinical suspicion of aGVHD by the treating physician is sufficient and biopsies are not required to pathologically confirm aGVHD. However, in situations where alternative diagnoses of drug effects or infection are not adequately ruled out on clinical suspicion alone, biopsies are recommended. - Patients must have a diagnosis of high-risk acute GVHD, defined as either
\-- Steroid-refractory GVHD
Progressive GVHD after at least 3 days of systemic corticosteroids ( 1 mg/kg/day of prednisone equivalent), OR
No improvement in GVHD after at least 7 days on 1 mg/kg/day of prednisone equivalent or insufficient improvement which warrants the addition of another agent, OR
Flare of GVHD symptoms during taper
High-risk, treatment-nave GVHD
AA3 risk by Ann Arbor GVHD scoring risk system
Treatment-nave: less than 3 days of therapy with systemic corticosteroids ( 1 mg/kg/day of prednisone equivalent)
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for 3 months after FMT
Ability to understand and the willingness to sign a written informed consent document, including the willingness to accept risk of unrelated donor stool
Ability to swallow large capsules

Exclusion Criteria

Participants who have initiated a new systemic treatment for steroid-refractory GVHD (institutional standard or investigational agent) within the 2 weeks prior to first dose of FMT. Treatment with FMT is allowed once the time since initiation of newest systemic therapy is 2 weeks or longer
Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Delayed gastric emptying syndrome or large hiatal hernia
Known chronic aspiration
Participants with a history of significant allergy to foods not excluded from the donor diet (excluded foods are tree nuts, peanuts, shellfish, eggs)
Pregnant and breast-feeding women are ineligible because they are not eligible for hematopoietic stem cell transplantation
HIV-positive participants are ineligible
Participants who are unable to swallow pills
Participants with end-stage liver disease (cirrhosis)
Participants with acute, active gastrointestinal infection (e.g., typhlitis, diverticulitis, appendicitis)
Participants with inflammatory bowel disease (e.g., ulcerative colitis, Crohn's)
Prior total colectomy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note